BiotechTube

Pemigatinib 4.5 MG

Phase 2Withdrawn
0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pancreas Cancer

Conditions

Pancreas Cancer

Trial Timeline

Jun 14, 2022 → Aug 31, 2025

NCT ID
NCT05216120

About Pemigatinib 4.5 MG

Pemigatinib 4.5 MG is a phase 2 stage product being developed by Incyte for Pancreas Cancer. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05216120. Target conditions include Pancreas Cancer.

What happened to similar drugs?

1 of 5 similar drugs in Pancreas Cancer were approved

Approved (1) Terminated (0) Active (4)
✅DaclizumabRocheApproved
🔄Alemtuzumab + Rabbit Anti-Human Thymocyte GlobulinAstellas PharmaPhase 3
🔄Enteric-coated mycophenolate sodium (EC-MPS)NovartisPhase 3
🔄Irinotecan Liposomal Injection + Oxaliplatin + 5Fluorouracil + Leucovorin + Nab-paclitaxel + GemcitabineIpsenPhase 3
🔄Gemcitabine + nab paclitaxelNovocurePhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05216120Phase 2Withdrawn

Competing Products

20 competing products in Pancreas Cancer

See all competitors
ProductCompanyStageHype Score
pemetrexedEli LillyPhase 2
27
Alemtuzumab + Rabbit Anti-Human Thymocyte GlobulinAstellas PharmaPhase 3
40
Romidepsin + Azacitidine + nab-Paclitaxel + Gemcitabine + Durvalumab + Lenalidomide capsuleAstraZenecaPhase 1/2
32
DurvalumabAstraZenecaPhase 2
27
MK-2206MerckPhase 2
35
Pembrolizumab + DEBIO1143MerckPhase 1
29
dovitinib lactate + gemcitabine hydrochloride + capecitabineNovartisPhase 1
29
AUY922NovartisPhase 2
27
dovitinib lactate + gemcitabine hydrochloride + paclitaxel albumin-stabilized nanoparticle formulationNovartisPhase 1
21
FOLFIRINOX + Oxaliplatin + Leucovorin + Irinotecan + 5-Fluorouracil (5-FU) + NIS793 + CapecitabineNovartisPhase 1
21
Enteric-coated mycophenolate sodium (EC-MPS)NovartisPhase 3
40
DaclizumabRocheApproved
43
Gemcitabine + panitumumabAmgenPhase 2
27
PF-03084014 + Gemcitabine + Nab-paclitaxel + PF-03084014 + Gemcitabine + Nab-paclitaxel + Gemcitabine + Nab-paclitaxelPfizerPhase 2
27
CRS-207 + CRS-207 + nivolumab + GVAX + CYBristol Myers SquibbPhase 2
35
Belatacept + methylprednisolone + Anti-thymocyte Globulin (Rabbit) + Tacrolimus + Mycophenolate mofetilBristol Myers SquibbPhase 2
27
AK154 + Cadonilimab + Ivonescimab (SMT112 or AK112) Injection + mFOLFORINOXAkesoPhase 1
36
Vemurafenib + SorafenibBayerPhase 2
36
sorafenib tosylate + everolimusBayerPhase 1
26
Irinotecan Liposomal Injection + Oxaliplatin + 5Fluorouracil + Leucovorin + Nab-paclitaxel + GemcitabineIpsenPhase 3
37